BRPI1007483A2 - biomarcadores associados com nefropatia. - Google Patents

biomarcadores associados com nefropatia.

Info

Publication number
BRPI1007483A2
BRPI1007483A2 BRPI1007483A BRPI1007483A BRPI1007483A2 BR PI1007483 A2 BRPI1007483 A2 BR PI1007483A2 BR PI1007483 A BRPI1007483 A BR PI1007483A BR PI1007483 A BRPI1007483 A BR PI1007483A BR PI1007483 A2 BRPI1007483 A2 BR PI1007483A2
Authority
BR
Brazil
Prior art keywords
nephropathy
biomarkers associated
biomarkers
Prior art date
Application number
BRPI1007483A
Other languages
English (en)
Inventor
Ching-Fang Lu
Chwei-Shiun Yang
Mary Ya-Ping Yeh
Tsai-Wei Hsu
Tzu-Ling Tseng
Wei-Ya Lin
Yi-Ting Chen
Original Assignee
Ind Tech Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ind Tech Res Inst filed Critical Ind Tech Res Inst
Publication of BRPI1007483A2 publication Critical patent/BRPI1007483A2/pt
Publication of BRPI1007483B1 publication Critical patent/BRPI1007483B1/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4728Details alpha-Glycoproteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/34Genitourinary disorders
    • G01N2800/347Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
BRPI1007483-0A 2009-01-28 2010-01-27 Método de diagnóstico de nefropatia in vitro, método in vitro para o monitoramento de progresso de nefropatia, método in vitro para o monitoramento da eficácia de um tratamento de nefropatia, método in vitro de avaliação de toxicidade renal de um agente e kit para diagnóstico de nefropatia BRPI1007483B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14778509P 2009-01-28 2009-01-28
US61/147,785 2009-01-28
PCT/CA2010/000096 WO2010085878A1 (en) 2009-01-28 2010-01-27 Biomarkers associated with nephropathy

Publications (2)

Publication Number Publication Date
BRPI1007483A2 true BRPI1007483A2 (pt) 2016-02-16
BRPI1007483B1 BRPI1007483B1 (pt) 2021-11-30

Family

ID=42395075

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1007483-0A BRPI1007483B1 (pt) 2009-01-28 2010-01-27 Método de diagnóstico de nefropatia in vitro, método in vitro para o monitoramento de progresso de nefropatia, método in vitro para o monitoramento da eficácia de um tratamento de nefropatia, método in vitro de avaliação de toxicidade renal de um agente e kit para diagnóstico de nefropatia

Country Status (12)

Country Link
US (5) US20100209948A1 (pt)
EP (1) EP2391653B8 (pt)
JP (1) JP5524241B2 (pt)
CN (1) CN102300875B (pt)
BR (1) BRPI1007483B1 (pt)
CA (1) CA2748852C (pt)
DK (1) DK2391653T3 (pt)
ES (1) ES2530574T3 (pt)
MX (1) MX2011007810A (pt)
PT (1) PT2391653E (pt)
TW (1) TWI397687B (pt)
WO (1) WO2010085878A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465980B2 (en) * 2009-01-28 2013-06-18 Industrial Technology Research Institute Urine and serum biomarkers associated with diabetic nephropathy
KR101732706B1 (ko) * 2015-06-05 2017-05-04 압타바이오 주식회사 신증 진단용 마커로서의 sh3yl1의 용도
EP3469372B1 (en) * 2016-06-10 2023-03-08 Warszawski Uniwersytet Medyczny Methods for diagnosis and monitoring using urine proteins as markers in iga nephropathy
CN119165152A (zh) * 2019-01-17 2024-12-20 国立大学法人冈山大学 IgA肾病发病可能性的判断方法及试剂盒

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4640909A (en) * 1985-05-07 1987-02-03 J. T. Baker Chemical Company Bonded phase of silica and carboalkoxyalkyl silanes for solid phase extraction
ES2258793T5 (es) * 1996-05-24 2010-01-25 Biogen Idec Ma Inc. Moduladores de la regeneracion tisular.
US6140076A (en) * 1996-12-06 2000-10-31 Schering Corporation Ig superfamily `dlair` receptors expressed in monocytes
ATE456656T1 (de) * 1996-12-06 2010-02-15 Schering Corp Isolierte gene aus säuger monozyten und betreffende reagentien
CA2356174A1 (en) * 1998-12-21 2000-06-29 Monash University Kidney disease detection and treatment
US20040029175A1 (en) * 1998-12-21 2004-02-12 Comper Wayne D. Method for kidney disease detection
AUPP784398A0 (en) * 1998-12-21 1999-01-21 Monash University Kidney disease detection and treatment
US6682917B1 (en) * 1999-06-28 2004-01-27 Takeda Chemical Industries, Ltd Protein having a ribonucleotide Reductase activity and a DNA thereof
ATE405670T1 (de) * 2002-05-13 2008-09-15 Arexis Ab Autoimmunerkrankungen und nadph-oxidase-defekte
GB0215509D0 (en) * 2002-07-04 2002-08-14 Novartis Ag Marker genes
DE602004022150D1 (de) * 2003-03-27 2009-09-03 Childrens Hosp Medical Center Verfahren und kit zum nachweis des frühstadiums einer nierentubuluszellenverletzung
DE602005023216D1 (de) * 2004-12-15 2010-10-07 Beth Israel Hospital Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen
US20060257481A1 (en) * 2005-04-21 2006-11-16 Decode Genetics Ehf. Sustained release formulation and dosing schedule of leukotriene synthesis inhibitor for human therapy
US20090304686A1 (en) * 2006-03-08 2009-12-10 Universotair Medisch Centrum Utrecht Interfering in activation of an immune cell by influencing interaction of lair and collagen
US7662578B2 (en) * 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
AU2007284651B2 (en) * 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
WO2008021431A2 (en) * 2006-08-14 2008-02-21 Xdx, Inc. Methods and compositions for diagnosing and monitoring the status of transplant rejection and immune disorders
JP5363984B2 (ja) * 2006-10-13 2013-12-11 メタボロン インコーポレイテッド 代謝年齢に関するバイオマーカー及びその使用方法
US20080187944A1 (en) * 2007-01-31 2008-08-07 Appa Rao Allam Butyrylcholinesterase as a marker of low-grade systemic inflammation
WO2008113363A1 (en) * 2007-03-21 2008-09-25 Bioporto Diagnostics A/S Diagnostic test for renal injury
EP2153234A2 (en) * 2007-05-11 2010-02-17 The Institutes for Pharmaceutical Discovery, LLC Methods for early diagnosis of kidney disease
US8465980B2 (en) * 2009-01-28 2013-06-18 Industrial Technology Research Institute Urine and serum biomarkers associated with diabetic nephropathy

Also Published As

Publication number Publication date
US20110086372A1 (en) 2011-04-14
CN102300875A (zh) 2011-12-28
ES2530574T3 (es) 2015-03-03
WO2010085878A1 (en) 2010-08-05
EP2391653B8 (en) 2015-09-30
MX2011007810A (es) 2011-09-30
PT2391653E (pt) 2015-02-13
US9442120B2 (en) 2016-09-13
CA2748852A1 (en) 2010-08-05
DK2391653T3 (en) 2015-02-09
US20110081667A1 (en) 2011-04-07
CA2748852C (en) 2019-05-28
EP2391653A4 (en) 2012-06-27
EP2391653B1 (en) 2014-12-31
JP2012516430A (ja) 2012-07-19
TW201033615A (en) 2010-09-16
US20110081668A1 (en) 2011-04-07
US8470547B2 (en) 2013-06-25
JP5524241B2 (ja) 2014-06-18
CN102300875B (zh) 2014-07-16
TWI397687B (zh) 2013-06-01
US20100209948A1 (en) 2010-08-19
EP2391653A1 (en) 2011-12-07
US20130266976A1 (en) 2013-10-10
BRPI1007483B1 (pt) 2021-11-30

Similar Documents

Publication Publication Date Title
BRPI1006166A2 (pt) gestos padrão.
BRPI1010653A2 (pt) refrigerador.
BRPI1011275A2 (pt) refrigerador.
BRPI1007047A2 (pt) Biorrefino irganosolv de cana-de-açúcar inteira.
BRPI1010301A2 (pt) composição.
EP2398939A4 (en) MICROARRAY WITH MICRO CHANNELS
BRPI0920069A2 (pt) biomarcadores
EP2265642A4 (en) BIOMARKERS
BRPI1009811A2 (pt) transmissão.
FR2947376B1 (fr) Sectionneur.
BRPI0924633A2 (pt) refrigerador.
IT1396487B1 (it) Convogliatore.
BR112012001062A2 (pt) laminados com microtextura.
DK2442870T3 (da) Pyrazinooxazepin-derivater.
EP2263086A4 (en) BIOMARKERS
IT1394665B1 (it) Granitore.
BRPI1011794A2 (pt) compartimento.
BR112012002612A2 (pt) calha.
EP2265641A4 (en) BIOMARKERS
BRPI1007483A2 (pt) biomarcadores associados com nefropatia.
IT1396642B1 (it) Statore.
FR2943510B1 (fr) Ombrelle.
BR112012000911A2 (pt) biomarcador.
ES1073526Y (es) Almohada.
BRPI1009521A2 (pt) pró-drogas.

Legal Events

Date Code Title Description
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25A Requested transfer of rights approved

Owner name: BIO PREVENTIVE MEDICINE CORPORATION (TW)

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/01/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.